Results 71 to 80 of about 28,144 (206)

The DOAC‐FRAIL Study—Same Dose, Different Story: Prevalence of Deviant Direct Oral Anticoagulant Levels in Nursing Home Residents

Journal of the American Geriatrics Society, EarlyView.
ABSTRACT Background Direct oral anticoagulants (DOACs) are prescribed using fixed dosing regimens, despite limited evidence on their pharmacokinetic behavior in nursing home residents. Participants and Setting One hundred nursing home residents are receiving apixaban, rivaroxaban, dabigatran, or edoxaban in multiple long‐term care facilities in the ...
Irme S. Franssen, Melanie J. de Jong, Lars Visseren, Daan Teerds, Dave Hellenbrand, Yvonne Henskens, Henri Spronk, Daisy J. A. Janssen, Dionne C. W. Braeken, Sander M. J. van Kuijk, Kristien Winckers, Fabienne J. H. Magdelijns   +11 more
wiley   +1 more source

Apixaban in bridge to transplant and destination LVAD - rationale and study design: the ApixiVAD trial. [PDF]

AIMS Use of novel anticoagulation in mechanical circulatory support is controversial. We report the rationale and design of the ApixiVad pilot trial, a pilot study testing the safety of apixaban as an anticoagulant in patients bridged to transplant ...
Ricardo Deveza, Christopher Hayward, Schnegg, Bruno, Deveza, Ricardo, Hayward, Christopher, Bruno Schnegg   +5 more
core   +2 more sources

Sleep characteristics and self‐reported sleep quality in the oldest‐old: Results from a prospective longitudinal cohort study

Journal of Sleep Research, Volume 34, Issue 2, April 2025.
Summary Little is known about the correlation between subjective perception and objective measures of sleep quality in particular in the oldest‐old. The aim of this study was to perform longitudinal home sleep monitoring in this age group, and to correlate results with self‐reported sleep quality.
Hugo Saner, Kevin Möri, Narayan Schütz, Philipp Buluschek, Tobias Nef   +4 more
wiley   +1 more source

Quick reference guide to apixaban [Corrigendum]

, 2017
Hurst KV, O’Callaghan JM, Handa A. Vascular Health and Risk Management. 2017:13 263–267.On page 264, Table 2 states that the apixaban dose should be reduced in patients with mild hepatic impairment and that it is not indicated in patients ...
Handa A, O'Callaghan JM, Hurst KV
core  

Oral Soft Tissue Biopsy in Patients Receiving Direct Oral Anticoagulants: A Prospective Cohort Study on Bleeding Outcomes

Oral Diseases, EarlyView.
ABSTRACT Background Direct oral anticoagulants (DOACs) are the first‐line therapy for stroke prevention in non‐valvular atrial fibrillation and venous thromboembolism. While evidence supports their continuation during routine dental procedures such as tooth extractions, data on oral soft tissue biopsies remain limited.
Rossana Izzetti, Chiara Cinquini, Antonio Barone, Marco Nisi   +3 more
wiley   +1 more source

Management of Left Atrial Appendage Thrombi and Spontaneous Echo Contrast

Pacing and Clinical Electrophysiology, EarlyView.
ABSTRACT Background To analyze the efficacy and safety of various anticoagulation strategies/regimen used for managing thrombus or spontaneous echo contrast in the left atrial appendage. Methods Thrombus or spontaneous echo contrast in the left atrial appendage was detected via transesophageal echocardiography in 83 patients, most often during a stroke
Timnou Bekouti Jean, Ravakiniaina Ranaivosoa Mialy, Ateba Ateba Nelly Stella, Tsague Kegni Hermann, Rambolarimanana Mansh, Ndobo Julia Valérie, Imbey Eheth Levy, Maury Philippe, Diawara Alpha, Roynard Jean Louis, Boombhi Jerome Hilaire   +10 more
wiley   +1 more source

Apixaban: Antikoagulan Oral Baru Penghambat Spesifik Faktor Xa [PDF]

, 2014
Apixaban adalah antikoagulan oral yang baru memperoleh persetujuan dari FDA pada tahun 2012. Mekanisme kerja apixaban sama dengan rivaroxaban, yaitu secara langsung menghambat faktor Xa, yang merupakan salah satu faktor koagulasi sehingga menghambat
Irawati, Sylvi
core   +2 more sources

Improving the Solubility and Bioavailability of Apixaban via Apixaban–Oxalic Acid Cocrystal

, 2016
Apixaban (apx), with a trade name of Eliquis, is a highly selective and efficacious inhibitor of blood coagulation factor Xa. Apixaban has poor solubility in water (0.028 mg/mL at 24 °C) and a relatively low oral bioavailability (about 50% for a single ...
Yu-Yu Ma (2593429), Tong-Bu Lu (1516030), Yong Chen (109188), Long Li (6555), Jia Yao (323339), Jia-Mei Chen (1516027)   +5 more
core   +1 more source

Apixaban enhances endogenous fibrinolysis in patients with atrial fibrillation [PDF]

, 2019
Aims Approximately 20% of ischaemic stroke patients exhibit spontaneous arterial recanalization, attributable to endogenous fibrinolysis, which strongly relates to improved functional outcome.
Gorog, Diana A., Arachchillage, Deepa RJ, Farag, M, Spinthakis, Nikolaos, Gue, Ying X., Lip, Gregory YH, Gue, Y, Spinthakis, N, Arachchillage, Deepa R.J., Lip, GYH, Wellsted, David, Wellsted, D, Gue, Ying, Farag, Mohamed, Lip, Gregory Y.H., Gorog, Diana A, Arachchillage, DRJ, Srinivasan, M, Srinivasan, Manivannan, Lip, Gregory Y H, Gorog, Diana, Gorog, DA   +21 more
core   +1 more source

Expert Consensus Statement: Committee on Implantable Devices and Committee on Social Issues, Japanese Heart Rhythm Society (JHRS) Statement on Remote Monitoring of Cardiac Implantable Electronic Devices

Journal of Arrhythmia, Volume 42, Issue 5, October 2026.
This statement of the Japanese Heart Rhythm Society (JHRS) provides comprehensive guidance for medical professionals and device manufacturers involved in RM. ABSTRACT Remote monitoring (RM) has been established as a standard tool for the management of patients with cardiac implantable electronic devices (CIEDs), offering advantages such as early event ...
Eiichi Watanabe, Nobuhiro Nishii, Akiko Maeda, Yoshiro Sakai, Katsuhito Fujiu, Makoto Suzuki, Ritsushi Kato, Haruhiko Abe, Takashi Noda, Hiroshi Tada, Masahiko Takagi   +10 more
wiley   +1 more source